Clinical trials: Cerebral Stroke
Hemiparesis
Post-stroke Motor Rehabilitation Using Functional Near-infrared Spectroscopy-based Brain-computer-interface
Chronic stroke survivors suffering from weaknesses or movement difficulties in their hand/arm are provided a system to aid in at-home rehabilitation for 6 weeks.
- Trial name
- fNIRS-PROMOTE (NCT05258591)
- Testing
- Axem Home
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Axem Neurotechnology Inc.
Ischemic Stroke, Systemic Embolism
Left Atrial Appendage Exclusion for Prophylactic Stroke Reduction Trial
This trial is a prospective, randomized, multicenter, multinational, blinded, superiority trial. The objective of this trial is to evaluate the effectiveness of left atrial appendage exclusion (LAAE) for the prevention of…
- Trial name
- LeAAPS (NCT05478304)
- Testing
- AtriClip LAA Exclusion System
- Where
- 138 sites in United States, Australia and 8 more
- Volunteers
- 6,573 people
- Sponsor
- AtriCure, Inc.
Sinus Node Disease
Clinical Benefits of the Closed Loop Stimulation in Sinus Node Disease
The study is designed as a multi-center, international, prospective, parallel, randomized, single blinded trial comparing the time to first primary endpoint event (Sustained Paroxysmal AF/Persistent AF or stroke/TIA) occurrence…
- Trial name
- B3 (NCT02579889)
- Testing
- DDD+CLS, DDD(R)
- Where
- 54 sites in China, Hungary and 7 more
- Volunteers
- 1,390 people
- Sponsor
- Biotronik SE & Co. KG
Deep Vein Thrombosis Leg, Stroke (in Patients With Atrial Fibrillation)
A Healthy Volunteer Study to Investigate the Blood Concentrations, the Effect on Blood Clotting and the Safety of Multiple Doses of DPOC-4088 Tablets in Different Doses.
A study to investigate the concentrations of a new drug DPOC-4088 in blood, and to study the effect of this drug on blood clotting parameters.
- Trial name
- NCT01647620
- Testing
- DPOC-4088
- Where
- Belgium
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Diakron Pharmaceuticals
Stroke, Secondary Prevention
Dabigatran Etexilate for Secondary Stroke Prevention in Patients With Embolic Stroke of Undetermined Source (RE-SPECT ESUS)
This trial will enroll approximately 6,000 patients with recent embolic stroke of unknown source (ESUS). Patients will be randomized to dabigatran or acetylsalicyclic acid (ASA) (1:1 ratio) and have visits every three months.
- Trial name
- NCT02239120
- Testing
- optional ASA as comedication, ASA 100 mg
- Where
- 569 sites in United States, Argentina and 40 more
- Volunteers
- 5,390 people
- Sponsor
- Boehringer Ingelheim
Ischemic Stroke
Effectiveness and Safety Trial of a New Ischemic Stroke Treatment Within 24 Hours From Stroke Onset (NEST-2)
The purpose of this pivotal study is to demonstrate safety and effectiveness of the NeuroThera® Laser System (referred to hereafter as NTS) in the treatment of Subjects diagnosed with acute ischemic stroke.
- Trial name
- NCT00419705
- Testing
- NeuroThera® Laser System
- Where
- 58 sites in United States, Germany and 2 more
- Volunteers
- 660 people
- Sponsor
- PhotoThera, Inc
Chronic Ischemic Stroke
Study of Modified Stem Cells (SB623) in Patients With Chronic Motor Deficit From Ischemic Stroke
Controlled study of stereotactic, intracranial injection of SB623 cells in patients with fixed motor deficits from ischemic stroke
- Trial name
- ACTIsSIMA (NCT02448641)
- Testing
- SB623 Implant (2.5M), SB623 Implant (5.0M)
- Where
- 65 sites in United States
- Volunteers
- 163 people
- Sponsor
- SanBio, Inc.
Cerebral Apoplexy
Single-dose Incremental Intravenous Injection of SY-007 in Healthy Subjects
This study is a single-dose incremental, randomized, double-blind, parallel, placebo-controlled study on safety, tolerance and pharmacokinetics healthy subjects.
- Trial name
- NCT04111523
- Testing
- SY-007
- Where
- China
- Volunteers
- 78 people, healthy volunteers welcome
- Sponsor
- Suzhou Yabao Pharmaceutical R&D Co., Ltd.
Cerebrovascular Accident
Headache Study to Compare Aggrenox Full Dose and Reduced Dose
Tolerability of a four weeks treatment with Aggrenox® modified release capsules b.i.d, compared to reduced dose during the first two weeks of treatment in a double-blind, randomized controlled parallel group comparison trial…
- Trial name
- NCT00274586
- Testing
- Aggrenox® modified release capsules
- Where
- Taiwan
- Volunteers
- 100 people
- Sponsor
- Boehringer Ingelheim
Subarachnoid Hemorrhage, Optical Imaging
A New Multi-parameter Neuromonitoring System to Save Patients' Lives in Stroke and Brain Injury
To assess the feasibility of a new neuromonitoring system (NeMoSystem including NeMo Probe and NeMo Patch) and the accuracy of the measurement values (cerebral blood flow (CBF); cerebral blood volume (CBV)) obtained.
- Trial name
- NCT01802762
- Testing
- NeMo Patch and NeMo Probe
- Where
- 2 sites in Austria, Switzerland
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- NeMoDevices AG
Myocardial Infarction, Stroke (Including Ischaemic Stroke and Transient Ischaemic Attack)
Study to Gather Information to What Extent Patients Follow the Treatment Regimen of Low-dose Aspirin for Primary and Secondary Prevention of Diseases of the Heart and Blood Vessels
This study aims to gather information to what extent patients follow the treatment regimen of low-dose aspirin for primary and secondary prevention of diseases of the heart and blood vessels.
- Conditions
- Myocardial Infarction, Stroke (Including Ischaemic Stroke and Transient Ischaemic Attack), Unstable Angina, Angina
- Trial name
- PALACE (NCT04097912)
- Testing
- Acetylsalicylic Acid (Aspirin, BAYE4465)
- Where
- 2 sites in Germany, United Kingdom
- Volunteers
- 99,999 people
- Sponsor
- Bayer
Acute Ischemic Stroke
Acute Ischemic Stroke Interventional Study
To assess safety of single IV (bolus + infusion) doses of ACT017 in patients with an acute ischemic stroke in addition to best emergency standard of care (including fibrinolysis by rtPA with or without added thrombectomy), with a…
- Trial name
- ACTIMIS (NCT03803007)
- Testing
- Intravenous ACT017 1000 mg
- Where
- France
- Volunteers
- 160 people
- Sponsor
- Acticor Biotech
Stroke
Smart Ankle-Foot Orthosis to Improve Stroke Outcomes: Smart AFO
The Smart Ankle-Foot Orthosis (Smart AFO) system is an investigational system that combines a diagnostic ankle-foot orthosis with a mobile application to assist clinicians in optimizing an AFO user's gait by adjusting AFO…
- Trial name
- NCT05619484
- Testing
- Smart AFO
- Where
- 3 sites in United States
- Volunteers
- 50 people
- Sponsor
- Orthocare Innovations, LLC
Stroke
PROTECTED TAVR: Stroke PROTECTion With SEntinel During Transcatheter Aortic Valve Replacement
To demonstrate that use of the Sentinel® Cerebral Protection System significantly reduces the risk of peri-procedural stroke (≤72 hours) after transcatheter aortic valve replacement (TAVR).
- Trial name
- PROTECTED TAVR (NCT04149535)
- Testing
- Sentinel® Cerebral Protection System
- Where
- 57 sites in United States, Australia and 4 more
- Volunteers
- 3,000 people
- Sponsor
- Boston Scientific Corporation
Peripheral Vascular Diseases
Screening DIVA - Diffuse Vascular Disease
Primary Objective: To investigate the value of the Edinburgh Claudication Questionnaire (ECQ) against the ankle-brachial index (ABI) in Canadian patients mainly followed in general practice, with documented acute coronary…
- Trial name
- NCT01076738
- Where
- Canada
- Volunteers
- 2,233 people
- Sponsor
- Sanofi
Atrial Fibrillation
A Dose-range Finding Study of MAA868 in Patients With Atrial Fibrillation
This study is a multicenter, randomized, subject and Investigator-blinded, placebo-controlled, parallel-group, multiple ascending dose-ranging study to evaluate the safety, tolerability, pharmacokinetics (PK), and…
- Trial name
- NCT04213807
- Testing
- MAA868 Cohort 1, MAA868 Cohort 2, MAA868 Cohort 3
- Where
- 6 sites in United States
- Volunteers
- 28 people
- Sponsor
- Anthos Therapeutics, Inc.
Ischemic Stroke
Augmenting Cerebral Blood Flow to Preserve the Penumbra Trial
The primary objective of the study is to demonstrate that SPG (Sphenopalatine Ganglion) stimulation started within 6 hours from stroke onset slows the expansion of the infarct core volume in acute ischemic stroke.
- Trial name
- ImpACT-P (NCT04014621)
- Testing
- SPG stimulation
- Where
- 4 sites in Georgia
- Volunteers
- 100 people
- Sponsor
- BrainsGate
Cerebral Infarction, Brain Ischemia
Japan Alteplase Clinical Trial (J-ACT): Efficacy and Safety Study of Tissue Plasminogen Activator (Alteplase) for Ischemic Stroke
Based on previous studies comparing Duteplase[a recombinant tissue plasminogen activator (rt-PA) very similar to alteplase] doses, we performed a clinical trial with 0.6mg/kg, which is lower than the internationally approved…
- Trial name
- NCT00147316
- Testing
- Alteplase
- Where
- Japan
- Volunteers
- 103 people
- Sponsor
- Tanabe Pharma Corporation
Ischemic Stroke, Acute
Single Bolus Non-immunogenic Staphylokinase in Patients With Acute Ischemic Stroke Within 4.5-24 Hours of Symptom Onset
Multicenter, double-blind, randomized, placebo-controlled phase III clinical trial. At the clinical sites, patients with acute ischemic stroke within 4.5-24 hours of symptom onset will be randomized to receive a single bolus…
- Trial name
- FRIDA-CT (NCT07324837)
- Testing
- non-immunogenic staphylokinase
- Where
- 17 sites in Russia
- Volunteers
- 990 people
- Sponsor
- Supergene, LLC
Atherosclerosis Cardiovascular Disease, Chronic Kidney Disease
A Study of Orforglipron (LY3502970) on Cardiovascular Outcomes in Adults With Atherosclerotic Cardiovascular Disease and/or Chronic Kidney Disease (ATTAIN-Outcomes)
The purpose of this study is to measure cardiovascular outcomes with orforglipron compared with placebo in participants with atherosclerotic cardiovascular disease (ASCVD) and/or chronic kidney disease (CKD).
- Trial name
- NCT07241390
- Testing
- Orforglipron
- Where
- 566 sites in Argentina, Australia and 36 more
- Volunteers
- 7,140 people
- Sponsor
- Eli Lilly and Company
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.